<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11710819</article-id><article-id pub-id-type="pmc">2375154</article-id><article-id pub-id-type="pii">6692045</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Wit</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Boer</surname><given-names>A C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>vd Linden</surname><given-names>G H M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stoter</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sparreboom</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Rotterdam Cancer Institute and University Hospital Rotterdam, IJsselland Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, The Netherlands</aff><pub-date pub-type="ppub"><month>10</month><year>2001</year></pub-date><volume>85</volume><issue>8</issue><fpage>1099</fpage><lpage>1101</lpage><history><date date-type="received"><day>29</day><month>05</month><year>2001</year></date><date date-type="rev-recd"><day>13</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>16</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>In view of the similarity in chemical structure of the available 5HT<sub>3</sub>-receptor antagonists it is assumed, whilst these agents all act at the same receptor, that failure to one agent would predict subsequent failure to all 5HT<sub>3</sub>-receptor antagonists. We conducted a randomized double blind trial of granisetron 3&#x02008;mg plus dexamethasone 10&#x02008;mg versus continued treatment with ondansetron 8&#x02008;mg plus dexamethasone 10&#x02008;mg in patients with protection failure on ondansetron 8&#x02008;mg plus dexamethasone 10&#x02008;mg during the first 24 hours following highly emetogenic chemotherapy. Of 40 eligible patients, 21 received ondansetron + dexamethasone and 19 received granisetron + dexamethasone. We found a significant benefit from crossing-over to granisetron after failure on ondansetron. Of the 19 patients who crossed over to granisetron, 9 patients obtained complete protection, whereas this was observed in 1 of the 21 patients continuing ondansetron, <italic>P</italic> = 0.005. These results indicate that there is no complete cross-resistance between 5HT<sub>3</sub>-receptor antagonists, and that patients who have acute protection failure on one 5HT<sub>3</sub>-receptor antagonist should be offered cross-over to another 5HT<sub>3</sub>-receptor antagonist. &#x000a9; 2001 Cancer Research Campaign<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">&#x02002;&#x02002;http://www.bjcancer.com</ext-link></p></abstract></article-meta></front></article>


